Grifols S A : May 8 2023Grifols realigns management structure to accelerate company performance and simplify its corporate governance

Grifols realigns management structure to

accelerate company performance and simplify its

corporate governance

Barcelona, Spain May 8, 2023 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announced that its Board of Directors has approved the realignment of the company's management team to accelerate Grifols' performance and simplify its corporate governance, ensuring a sharper focus on delivering results.

In addition to his role as Executive Chairman, Thomas Glanzmann has been appointed to the position of CEO, effective immediately. He will be responsible for the company's business decisions while creating and implementing its short- and long-term strategies with the management team.

Victor Grifols Deu will become Chief Operating Officer, focused on managing the day-to-day business, with all operating functions reporting to him. He will continue as a member of the company's Board of Directors.

Raimon Grifols, currently Grifols Vice Chairman, will in addition to his Board duties assume the role of Chief Corporate Officer, centered on optimizing the value of Grifols Corporate affiliates and partnerships, as well as leading key corporate initiatives.

Thomas Glanzmann commented: "I am confident these changes will position Grifols for the next chapter of growth, helping accelerate our performance to deliver results and meet our commitments to all of the company's stakeholders."

INVESTORS:

Grifols Investors Relations & Sustainability [e-mail] [e-mail] - [e-mail]. [phone]

MEDIA CONTACTS:

Grifols Press Office
[e-mail]
Tel. [phone]
Spain
Duomo Comunicación	International
Tel.: [phone]	Finsbury Glover Hering
Raquel Lumbreras (Tel. [phone])	Email:[e-mail]
[e-mail]	Tel.: [phone]
Borja Gómez (Tel. [phone])
[e-mail]
	Page 1 of 2

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with more than 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex- 35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Page 2 of 2